Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8339116 | 0.83 | GABRP (0.35) | HTTKMT2A | |
| SCHEMBL16394692 | 0.75 | HTT (0.41) | HTTKMT2APTGDR2HSD17B10SMN1; SMN2 | |
| SCHEMBL25623946 | 0.74 | HTT (0.35) | HTTKMT2APTGDR2HSD17B10SMN1; SMN2 | |
| SCHEMBL15053158 | 0.74 | S1PR1 (0.37) | HTTKMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL7843693 | 0.72 | PLAU (0.42) | HTTKMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL15052654 | 0.72 | HTT (0.34) | HTTKMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL31143948 | 0.72 | CTSD (0.38) | HTTKMT2APTGDR2HSD17B10SMN1; SMN2 | |
| SCHEMBL15052497 | 0.69 | RAB9A (0.38) | HTTKMT2ASMN1; SMN2 | |
| SCHEMBL17591656 | 0.68 | KDM4E (0.41) | KMT2A | |
| SCHEMBL16132375 | 0.67 | SSTR4 (0.32) | HTTKMT2APTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | HTT 155/4885KMT2A 2702/4885PTGDR2 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.